Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FRS fares well in second ad review

This article was originally published in The Tan Sheet

Executive Summary

The Electronic Retailing Self-Regulation Program approves all but one of the claims FRS Co. makes for its FRS Health Energy drinks. ERSP recommended and the Culver City, Calif., firm agreed claims that the ingredient quercetin supports "the immune system like no other antioxidant" and is "clinically proven to boost energy" should be changed to avoid implying no other antioxidant boosts energy. In a March 16 report following a review prompted by an anonymous complaint, ERSP said FRS' evidence supported claims that its products boost energy, increase focus and that its version of quercetin is "the purest" available. In a previous review, the Council of Better Business Bureaus' National Advertising Division said FRS Healthy Energy ads featuring Lance Armstrong must clarify he is endorsing the product as a celebrity, not as a professional cyclist (1"The Tan Sheet" Sept. 22, 2008). Like the ERSP review, NAD agreed the firm supported its claims. In its statement, FRS said it "supports industry's efforts to ensure integrity in the marketplace.

You may also be interested in...

Celebrity Vs. Expert Endorsement Subject Of NAD Review

Future ads for FRS Healthy Energy drinks that feature Lance Armstrong must clarify that the athlete is endorsing the product as a celebrity, not as a professional cyclist, according to the National Advertising Division

Novartis Q4 Preview: Launches Likely To Deliver

Having had a very fruitful year in terms of regulatory approvals, the Swiss major will reveal how successful its new products have been commercially. Of particular interest will be the performance of eye drug Beovu as it takes on Bayer's rival Eylea.

Executives On The Move: New Picks For Finance Posts At Cambrex And Editas Medicine, And Zimmer Biomet Fills Communications Spot

Gene-editing company Editas Medicine appoints a new CFO, while Affimed and NexImmune bring new chief medical officers on board.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts